?Brinzolamide Intermediate (CAS 160982-10-5) | High-Quality API Synthesis Building Block?
?Google Search Keywords?: Brinzolamide Intermediate, CAS 160982-10-5, Carbonic Anhydrase Inhibitor Intermediate, API Synthesis, Pharmaceutical Intermediates

?? ?Product Overview?
Brinzolamide Intermediate (CAS 160982-10-5) is a key chemical building block in the synthesis of Brinzolamide, a carbonic anhydrase inhibitor used to treat glaucoma and ocular hypertension. This intermediate ensures efficient and scalable production of high-purity active pharmaceutical ingredients (APIs).
?Primary Function?: Critical precursor in Brinzolamide API manufacturing.
?Applications?: Pharmaceutical synthesis, generic drug development, process optimization.

? ?Key Advantages?
? ?High Yield & Purity?

• Purity ≥99% (HPLC), optimized for seamless API synthesis.

? ?Process Efficiency?

• Reduces synthesis steps, enhancing cost-effectiveness and production timelines.

??? ?Stability?

• Stable under standard storage conditions, ensuring consistent performance.

?? ?Applications?

1. ?API Manufacturing?: Core component in Brinzolamide production.

2. ?Generic Drug Development?: Supports cost-effective alternatives to branded medications.

3. ?Process Chemistry?: Used in route scouting and optimization studies.

?? ?Quality Certifications?

• Rigorously tested via ?HPLC, GC, and NMR? (compliant with ICH Q7 and USP/EP standards).

• Batch-specific Certificate of Analysis (CoA) ensures traceability and compliance.

?? ?Market Trends?
The global pharmaceutical intermediates market is expected to grow at ?6.2% CAGR (2023-2030)?, fueled by rising demand for glaucoma therapies and generic APIs. Brinzolamide intermediates are pivotal in meeting the needs of expanding ophthalmic drug manufacturing.

?? ?Why Choose Us??

• Custom synthesis and bulk order capabilities.

• Fast global delivery with cold-chain support.

• Expert technical guidance for API development.